Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

Journal of Cellular and Molecular Medicine(2020)10.1111/jcmm.14927Source: DataRank Database

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia is a research paper published in Journal of Cellular and Molecular Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

Linked data & code

gen nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.17)OA: goldTopics (64)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Chengcheng Meng,Abigail E. Case ORCID,Hong L. Tiv ORCID,Prafulla C. Gokhale ORCID,Sara J. Buhrlage ORCID

Live enrichment

PubMed:31967735 PMC:PMC7077552 OpenAlex:https://openalex.org/W3002123963

National Institutes of Health

Grant: PO1CA66996

NCI NIH HHS

Grant: P01 CA066996

NCI NIH HHS

Grant: P50 CA206963

FWCI

2.17

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcmm.14927

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcmm.14927

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjcmm.14927

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.14927

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/jcmm.14927

Fields of Study

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAniline CompoundsAnimalsAntineoplastic AgentsApoptosisBenzimidazolesBenzothiazolesCell Line, TumorCell ProliferationDrug SynergismGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteMiceMutationPhenylurea CompoundsPiperidinesProtein Kinase InhibitorsPyrazinesSorafenibStaurosporineSyk Kinasefms-Like Tyrosine Kinase 3

MeSH Terms

Syk KinaseSorafenibAniline CompoundsAnimalsAntineoplastic AgentsBenzimidazolesDrug SynergismHumansMutationPhenylurea CompoundsPiperidinesPyrazinesLeukemia, Myeloid, AcuteGene Expression Regulation, NeoplasticApoptosisStaurosporineCell Line, TumorProtein Kinase InhibitorsCell ProliferationMicefms-Like Tyrosine Kinase 3Benzothiazoles

Keywords

MidostaurinSorafenibCancer researchMedicineMyeloid leukemiaFms-Like Tyrosine Kinase 3PharmacologyOncologyBiologyMutationsynergyAcute myeloid leukaemiaSykQuizartinibCrenolanibGilteritinibNon-mutant Flt3

Sustainable Development Goals

SDG 0: Good health and well-being

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

FAIR Checklist

Authors (14)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)